Vistagen Therapeutics (VTGN) Set to Announce Earnings on Thursday

Vistagen Therapeutics (NASDAQ:VTGN) will release its earnings data after the market closes on Thursday, November 7th. Analysts expect Vistagen Therapeutics to post earnings of ($0.40) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Vistagen Therapeutics (NASDAQ:VTGN) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.06. Vistagen Therapeutics had a negative return on equity of 35.12% and a negative net margin of 3,421.85%. The company had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.30 million. During the same period in the previous year, the company posted ($0.94) earnings per share. On average, analysts expect Vistagen Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Vistagen Therapeutics Stock Down 2.2 %

NASDAQ VTGN opened at $3.15 on Wednesday. Vistagen Therapeutics has a twelve month low of $2.45 and a twelve month high of $5.86. The firm has a market capitalization of $85.24 million, a PE ratio of -2.13 and a beta of 0.78. The stock’s 50 day moving average is $3.11 and its 200 day moving average is $3.58.

Wall Street Analyst Weigh In

Separately, William Blair upgraded Vistagen Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th.

About Vistagen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.